Skip to main
CELC

Celcuity (CELC) Stock Forecast & Price Target

Celcuity (CELC) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Celcuity Inc. has demonstrated a substantial stock price appreciation of approximately 608% year-to-date, significantly outperforming key market indices which include a 28.7% gain for the Nasdaq Biotechnology Index and a 14.5% increase for the S&P 500. The company's optimistic outlook is further reinforced by increased sales estimates for its lead candidate, gedatolisib, which have risen to $70 million, $462 million, and $827 million for 2023, 2024, and 2025 respectively, reflecting expedited regulatory reviews and enhanced market share in both PIK3CA wild-type and mutant patient populations. The upcoming topline data from the VIKTORIA-1 trial is expected to yield a favorable risk/reward profile, bolstered by positive clinical validation supporting gedatolisib's efficacy across varying patient mutations, thereby strengthening investor confidence in the stock's potential.

Bears say

Celcuity Inc's financial outlook is concerning due to a projected $45 million total expenditure, which includes a $35 million decrease in R&D spending, indicating potential issues in their development pipeline. The company's cautious stance is attributed to the risks associated with upcoming regulatory decisions and their ability to compete against larger pharmaceutical companies with established market presence, particularly if FDA approval delays occur or if pricing pressures emerge from payors. Furthermore, the current valuation of $4.3 billion may not accurately reflect the potential for adoption or revenue per patient, leading to fears of a stock price reevaluation if anticipated financial metrics do not materialize.

Celcuity (CELC) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Celcuity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Celcuity (CELC) Forecast

Analysts have given Celcuity (CELC) a Buy based on their latest research and market trends.

According to 9 analysts, Celcuity (CELC) has a Buy consensus rating as of Apr 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $109.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $109.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Celcuity (CELC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.